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Abstract
Purpose 111In (typically as [111In]oxinate3) is a gold standard
radiolabel for cell tracking in humans by scintigraphy. A long
half-life positron-emitting radiolabel to serve the same pur-
pose using positron emission tomography (PET) has long
been sought. We aimed to develop an 89Zr PET tracer for cell
labelling and compare it with [111In]oxinate3 single photon
emission computed tomography (SPECT).
Methods [89Zr]Oxinate4 was synthesised and its uptake and
efflux were measured in vitro in three cell lines and in human
leukocytes. The in vivo biodistribution of eGFP-5T33 murine
myeloma cells labelled using [89Zr]oxinate4 or [
111In]oxinate3
was monitored for up to 14 days. 89Zr retention by living
radiolabelled eGFP-positive cells in vivo was monitored by
FACS sorting of liver, spleen and bone marrow cells followed
by gamma counting.
Results Zr labelling was effective in all cell types with yields
comparable with 111In labelling. Retention of 89Zr in cells
in vitro after 24 h was significantly better (range 71 to
>90 %) than 111In (43–52 %). eGFP-5T33 cells in vivo
showed the same early biodistribution whether labelled with
111In or 89Zr (initial pulmonary accumulation followed by
migration to liver, spleen and bone marrow), but later trans-
location of radioactivity to kidneys was much greater for 111In.
In liver, spleen and bone marrow at least 92 % of 89Zr
remained associated with eGFP-positive cells after 7 days
in vivo.
Conclusion [89Zr]Oxinate4 offers a potential solution to the
emerging need for a long half-life PET tracer for cell tracking
in vivo and deserves further evaluation of its effects on sur-
vival and behaviour of different cell types.
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Introduction
Cell tracking by scintigraphy with radionuclides has been
routine in nuclear medicine for 30 years [1] for tracking
autologous leukocytes to detect sites of infection/
inflammation [2, 3]. The standard radiolabelling methodology
has been non-specific assimilation of lipophilic, metastable
complexes of 111In (with oxine [4], tropolone [5] and occa-
sionally other bidentate chelators [6]), and later 99mTc [7].
New insight in immunology is creating interest in imaging
the migration of individual immune cell types (e.g. eosino-
phils [8, 9], neutrophils [8, 9], T-lymphocytes [10–12],
and dendritic cells [13]) in cancer, atherosclerosis, stroke,
transplant and asthma. Regenerative medicine and cell-based
therapies are creating new roles for tracking stem cells and
chimeric antigen receptor-expressing T-lymphocytes [14, 15].
Conventional labelling methods have been applied in some of
these areas, but for clinical use some of these new applications
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will require detection of small lesions and small numbers of cells
beyond the sensitivity of gamma camera imaging with 111In
(e.g. coronary artery disease, diabetes, neurovascular inflamma-
tion and thrombus), creating a need for positron-emitting radio-
labels to exploit the better sensitivity, quantification and resolu-
tion of clinical positron emission tomography (PET).
So far the search for positron-emitting radiolabels for cells has
met with limited success. The near-ubiquitous presence of glu-
cose transporters allows labelling with [18F]fluorodeoxyglucose
(FDG), but labelling efficiencies are highly variable, the radiola-
bel is prone to rapid efflux and the short half-life (110min) of 18F
allows only brief tracking [16–18]. 68Ga can be used to label
cells [19] but it too has a short half-life (68 min). 64Cu offers a
longer (12 h) half-life and efficient cell labelling using lipophilic
tracers (complexes of PTSM [11, 20–22], GTSM [23],
diethyldithiocarbamate [24] and tropolonate [25]), but rapid
efflux of label from cells is a persistent problem and a still longer
half-life would be preferred. A “PET analogue” of
[111In]oxinate3, capable of cell tracking over 7 days or more,
would be highly desirable but is not yet available.
89Zr is a long half-life positron emitter that could meet this
need [26, 27]. The favoured oxidation state of zirconium is 4+
(compared to 3+ for indium), but the parallels between the two
metals in reactivity and preferred ligand types suggest that the
mechanism exploited to label cells with 111In (i.e. lipophilic
metastable chelates entering cells and subsequently dissociat-
ing) might be exploited in the case of 89Zr. Tetravalent zirco-
nium forms ZrL4 complexes with monobasic bidentate li-
gands such as oxinate [28], tropolonate [29] and
hydroxamates [30], analogous to InL3 [31, 32]. Here we
describe the first synthesis of [89Zr]oxinate4 and comparison
with [111In]oxinate3 for labelling several cell lines and track-
ing eGFP-5T33 cells in mice. eGFP-5T33 is a syngeneic
murine multiple myeloma model originating from the
C57Bl/KaLwRij strain [33], engineered to express enhanced
green fluorescent protein (eGFP). It was chosen for this work
because the fate of the cells after i.v. inoculation is known
from the literature [34–36] and prior work in our laboratory.
Like human multiple myeloma, 5T33 develops elevated se-
rum immunoglobulin levels and osteolytic disease [33, 37].
Intravenously injected cells migrate exclusively to the liver,
spleen and bone marrow [37].
Materials and methods
Radiochemistry
89Zr was supplied as Zr4+ in a 0.1 M oxalic acid (PerkinElmer,
Seer Green, UK), brought to pH 7 with 1 M Na2CO3 and
diluted to 500 μl with water. This “neutralised [89Zr]oxalate”
was used as a control in cell labelling experiments in vitro. To
prepare [89Zr]oxinate4 the above neutralised [
89Zr]oxalate
solution (typically 20–90 MBq) was added to a glass reaction
vessel containing 500 μl of a 1 mg/ml 8-hydroxyquinoline
solution in chloroform. The vessel was shaken for 15 min and
the product [89Zr]oxinate4 was recovered from the chloroform
phase by evaporation, redissolved in dimethyl sulfoxide
(DMSO, 10–20 μl) and diluted with phosphate-buffered sa-
line (PBS, 1–3 ml) or cell culture medium. Full details are
provided in the Electronic Supplementary Material (ESM).
Cell labelling initial evaluation
[89Zr]Oxinate4 was evaluated in vitro in three cell lines: cul-
tured J774 mouse macrophages [38], MDA-MB-231 breast
cancer cells [39] and eGFP-5T33 murine myeloma cells [40];
and in leukocytes from healthy volunteers. Studies were ap-
proved by an independent UK National Research Ethics
Committee and complied with the Declaration of Helsinki.
Culture methods and leukocyte preparation and labelling are
described in the ESM. Labelling of cell lines was initially
evaluated as follows: To triplicate suspensions of 106 cells in
450 μl of serum-depleted [i.e. not supplemented with foetal
bovine serum (FBS)] culture medium in glass tubes were
added 0.05 MBq of [89Zr]oxinate4 (or neutralised
[89Zr]oxalate) in 50 μl of serum-depleted medium. After
incubation for up to 60 min at room temperature the tubes
were centrifuged (5 min, 490 g), 450 μl of supernatant was
removed and both supernatant and pellet were counted in a
Wallac 1282CompugammaUniversal GammaCounter. Pellet
activity was corrected for the residual 50 μl of supernatant.
Similar methods were used with higher activities (up to
40 MBq) and cell numbers (up to 5 x 107) and with
[111In]oxinate3 for comparison. After these initial evaluations
a standard labelling incubation period of 30 min was adopted
for all subsequent biological evaluation.
Efflux of radioactivity from cells
Cells were labelled with [89Zr]oxinate4 or [
111In]oxinate3 in
glass tubes (106 cells and 0.05MBq 89Zr or 0.1 MBq 111In per
tube), washed three times with PBS, resuspended in culture
medium (500 μl) and incubated at 37 °C. Samples taken at
intervals up to 24 h were centrifuged and pellets and superna-
tants counted.
Cell viability
To assess the effect of [89Zr]oxinate4 on viability of eGFP-
5T33 cells, samples of 1.2–1.4×106 cells (initially 93 % via-
ble based on trypan blue exclusion) were radiolabelled as
described above, washed and incubated in 20 ml of RPMI-
1640 (supplemented with 10% FBS, 200 U/l penicillin, 0.1 g/
l streptomycin and 2 mM L-glutamate) in T75 tissue culture
flasks at 37 °C (5 % CO2). After 24 h, viability of these cells
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and of controls (treated similarly except for omission of
[89Zr]oxinate4) was determined by trypan blue exclusion.
Labelling eGFP-5T33 cells for in vivo cell tracking
Cells were labelled with [111In]oxinate3 or [
89Zr]oxinate4 as
described above [4×106 and 5×107 eGFP-5T33 cells/tube; ca.
0.5 MBq per tube for ex vivo organ counting and up to
40 MBq per tube for PET/single photon emission computed
tomography (SPECT) imaging], washed three times with PBS
and resuspended in 0.2–1 ml of sterile PBS ready for inocu-
lation. Cell viabilities were determined by trypan blue exclu-
sion. To obtain radiolabelled cell lysates, labelled eGFP-5T33
cells were subjected to three cycles of flash-freezing in liquid
nitrogen and rapid heating to 90 °C before resuspending in
200–500 μl PBS and repeatedly passing through 27- and 29-
gauge needles until visibly homogeneous.
Ex vivo cell tracking of eGFP-5T33murinemultiple myeloma
Animal experiments complied with the Animals (Scientific
Procedures) Act (UK 1986) and Home Office (UK) guide-
lines. Male C57Bl/KaLwRij mice, 6–7 weeks old (Harlan,
UK) were acclimatised for >7 days with ad libitum access to
water and diet. To assess early tissue distribution ten mice
were inoculated via the tail vein with 2×106 cells labelledwith
0.6–0.8 MBq [89Zr]oxinate4 in 100 μl sterile PBS and culled
by cervical dislocation at 9 (n=3), 24 (n=4) and 48 h (n=3)
post-injection for ex vivo tissue counting. The longer-term
biodistribution of [89Zr]oxinate4- and [
111In]oxinate3-labelled
cells was compared in three mice injected with 0.9 MBq
[89Zr]oxinate4 in 6×10
6 cells and three with 1.7 MBq
[111In]oxinate3 in 5×10
6 cells), culled by cervical dislocation
after 7 days. Major thoraco-abdominal organs, the left femur
and thigh muscle were excised, weighed and gamma-counted.
Ex vivo fluorescence-activated cell sorting (FACS)
Mice were culled by CO2 asphyxiation 2 (n=3) and 7 days
(n=3) after inoculation with 107 eGFP-5T33 cells labelled
with 1.5MBq [89Zr]oxinate4. Livers, spleens and femora were
harvested. Livers and spleens were homogenised. Homoge-
nates were filtered through a 40-μm cell strainer (BD, USA),
diluted to 107 cells/ml in ice-cold FACS buffer [1v/v% FBS,
2 μM ethylenediaminetetraacetate (EDTA) in PBS] and kept
on ice. Marrow was flushed from the femora with 5–6 ml of
ice-cold FACS buffer, filtered through a 40-μm cell strainer
and kept on ice. Samples were analysed on a BD FACSAria
III cell sorter (BD, USA) collecting 10,000 each of eGFP-
positive and eGFP-negative cells (day 2) and 20,000 each of
eGFP-positive and eGFP-negative cells (day 7) for gamma
counting.
PET imaging
Preclinical PET/CT images were acquired in a nanoScan®
PET/CT (Mediso, Budapest, Hungary) scanner with mice
under isoflurane (2 % in oxygen) anaesthesia, starting 60 s
before inoculation with 107 eGFP-5T33 cells labelled with
5MBq [89Zr]oxinate4 in a 200-μl bolus via the right lateral tail
vein. Scanning was continued for 2 h and repeated 1, 2, 5, 7
and 14 days after inoculation, acquiring a CT scan after each
PET scan. Control mice were inoculated with [89Zr]oxinate4
(4MBq in 100 μl saline) but no cells, and lysate from 1.1×106
cells labelled with 0.9 MBq [89Zr]oxinate4, and scanned be-
tween 5 and 50 min post-injection and at 24 h post-injection.
SPECT imaging
SPECT scans were acquired for 4 h immediately after inocu-
lation of 107 eGFP-5T33 cells labelled with 10 MBq
[111In]oxinate3 in a 200-μl bolus, using a nanoSPECT/CT
(silver upgrade, Mediso, Budapest, Hungary) with four high-
resolution multi-pinhole collimators. Further SPECT scans
were acquired 1, 2, 3, 5 and 7 days post-injection, each
followed by a CT scan. As a control, cell lysate from ca.
1.1×106 cells labelled with 1.1 MBq [111In]oxinate3 was
injected intravenously followed by SPECT/CT scanning at
60 and 105 min post-injection.
Statistics
Statistical significance was tested using a two-tailed Student’s
t test with significance defined as a confidence level of 95 %
or above.
Results
Synthesis and quality control of [89Zr]oxinate4
A biphasic system, with the radiolabel in aqueous solution and
oxine in chloroform, was used to synthesise [89Zr]oxinate4.
Yields of radioactivity in the chloroform phase were ca. 60 %.
Repeated extraction with further aliquots of oxine solution in
chloroform led to increased yields (see ESM). Both chloro-
form extraction and instant thin-layer chromatography (ITLC,
Rf =0.9, cf. zero for [
89Zr]oxalate) before and after dilution of
the DMSO solution in saline/serum-depleted RPMI-1640 re-
producibly showed radiochemical purity above 99 %.
Cell labelling
Initial labelling experiments in all cell lines and leukocytes
showed rapid accumulation of [89Zr]oxinate4, approaching
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plateau levels by 30 min (Fig. S1). In all subsequent labelling
experiments a standard labelling incubation time of 30 min
was adopted, leading to labelling efficiencies in the range of
40–61 % for up to 9 × 107 cells, as shown in Table 1. By
contrast, uptake of neutralised [89Zr]oxalate, although increas-
ing with time, was much lower and never exceeded 5 %
(Fig. S1).
Efflux from cells
Efflux of 89Zr from all three labelled cell lines in vitro was
significantly slower than efflux of 111In; at 24 h, >90% of 89Zr
was retained by J774 macrophages (cf. 51.9 % for 111In),
>83 % by MDA-MB-231 cells (cf. 43.7 % for 111In) and
>71 % by eGFP-5T33 cells (Fig. S2). Retention of 89Zr in
leukocytes after 24 h was 85.1 and 86.9 % (n=2).
Cell viability
[89Zr]Oxinate4 labelling reduced viability of eGFP-5T33 cells
from 93 % before labelling to 76.3±3.2 % immediately post-
labelling [cf. 89.7±1.2 % (p=0.01) for 89Zr-free controls], but
there was no further significant loss in viability 24 h after
labelling (87.3±4.0 %, cf. 89.3±3.0 % for 89Zr-free controls,
n=3).
In vivo cell tracking
PET imaging after inoculation of [89Zr]oxinate4-labelled
eGFP-5T33 myeloma cells demonstrated accumulation of
cells in lungs at 30 min followed by migration to liver, spleen
and bone marrow by 24 h. Ex vivo tissue sampling (Table 2
and Fig. S3) confirmed location of radioactivity predominant-
ly in liver, spleen and bone marrow between 9 and 48 h.
The in vivo biodistribution of 89Zr-labelled eGFP-5T33
myeloma cells was compared alongside that of cells from
the same culture labelled with 111In longitudinally over 7 days
using PET and SPECT imaging and ex vivo tissue sampling
up to 7 days (Fig. 1, Table 3). Cell viabilities were 85–95 %
with both radiolabels before inoculation. PET and SPECT
images between 30 min and 7 days are shown in Fig. 2. A
PET image acquired on day 14 is shown in Fig. S4 and ex vivo
tissue uptake data for both radionuclides at 7 days are listed in
Table 3. 111In SPECT and 89Zr PET showed qualitatively
similar migration patterns in the first few hours after inocula-
tion. However, there was significantly higher %ID/g of 89Zr
than 111In in the main target organs (liver, spleen, bone) at
7 days (by factors of 1.5, 1.8 and 1.8, p=0.03, p=0.02 and p=
0.03, respectively) (Table 3). The %ID/g of 111In in kidneys
increased with time, reaching 3.75-fold higher (p<0.0001)
than that of 89Zr by 7 days.
When radiolabelled cell lysates were injected i.v., uptake in
the liver, spleen and skeleton was observed but there was also
a much more marked accumulation in the kidneys, both for
111In and 89Zr (Fig. 3). Intravenously injected [89Zr]oxinate4
gave a qualitatively similar biodistribution to labelled cell
lysates but there was also significant uptake in the heart and
lungs after 24 h.
FACS sorting (based on eGFP fluorescence) of organ ho-
mogenates from animals culled 2 and 7 days after inoculation
with cells labelled with [89Zr]oxinate4 showed that the eGFP-
positive cells contained more activity per cell (by a factor of
>23 at 2 days and a factor of >12 at 7 days) than eGFP-
negative cells (p<0.02) (Fig. 4). Example FACS data are
reported in Fig. S5.
Discussion
A general-purpose radiolabel that allows the advantages of
PET to be implemented for tracking cells in vivo over several
days should satisfy several criteria: the radioisotope must have
a suitably long half-life and appropriate positron energy and
abundance, convenient and economic availability, a simple
and efficient labelling procedure, no major selectivity for
different cell types, minimal effects on cell survival and func-
tion in vivo and minimal efflux from cells. These criteria
should be met at least as well as [111In]oxinate3 meets them
and better than positron-emitting alternatives reported to date.
We have synthesised a lipophilic, metastable complex,
[89Zr]oxinate4, evaluated it biologically in a range of cell lines
in vitro and selected one cell line (eGFP-5T33 myeloma cells)
for evaluation in vivo. The results indicate that [89Zr]oxinate4
Table 1 Cell labelling efficiencies with [89Zr]oxinate4 and [
111In]oxinate3 in different cell types
Cell number
(concentration)
Labelling efficiency 89Zr Labelling
efficiency 111In
Medium
J774 mouse macrophages 106 (2×106/ml) 23.1±1.8 (n=3) (not optimised) – Cell culture medium (DMEM)
MDA-MB-231 breast cancer 106 (2×106/ml) 20.2±3.7 (n=3) (not optimised) – Cell culture medium (DMEM)
eGFP-5T33 mouse myeloma <5×107 (<1.3×107/ml) 43.2±6.4 (n=3) 96, 82 (n=2) Cell culture medium (RPMI 1640)
Human leukocytes 9×107 (4.5×107/ml) 54.3±11.9 (n=3) 46.8±12.3 (n=3) Saline
2×107 (107/ml) 47.0±10.5 (n=3) – Saline
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meets these criteria. The half-life of 89Zr is 3.3 days (longer
than that of 111In and potential positron-emitting competitors
64Cu, 18F and 68Ga); only 124I (4.2 days) is comparable in this
respect but cell labelling with 124I has not been reported. The
positron abundance and energies and gamma emissions of 89Zr,
although not ideal compared to 18F, 64Cu and 68Ga, proved
adequate to give better-resolved images than SPECT with
99mTc in a direct comparison (human sentinel node imaging)
[41]. 89Zr is now commercially and economically available as a
GMP product. The cell labelling procedure described here is
simple, indeed identical to that used with [111In]oxinate3; good
labelling efficiencies are achieved within a few minutes. The
labelling method is effective for several different cell lines and
human leukocytes. The survival of labelled eGFP-5T33 cells
in vitro is comparable to or better than that of [111In]oxinate3-
labelled cells and not significantly different to that of control
cells treated identically except for omission of radioactivity.
While leukocytes are efficiently labelled and show good reten-
tion of radioactivity at 24 h, the effects of labelling on survival
and function have not been determined, and further investiga-
tion of these aspects in the different leukocyte types are re-
quired. The in vivo biodistribution and FACS sorting data
suggest that labelled eGFP-5T33 cells remain viable for at least
7 days, since the 89Zr-labelled cells continue to express eGFP
after this period in vivo. Retention of 89Zr by cells studied here
in vitro over 24 h compares well with published cell radiola-
bels; it is significantly better than that of 111In and markedly
Table 2 Tissue distribution of 89Zr after i.v. inoculation of [89Zr]oxinate4-labelled eGFP-5T33 cells in C57Bl/KaLwRij mice
Organ 89Zr-oxine 89Zr-oxine 89Zr-oxine 89Zr-oxine 89Zr-oxine 89Zr-oxine
9 h (n=3) 9 h (n=3) 24 h (n=4) 24 h (n=4) 48 h (n=3) 48 h (n=3)
%ID/g %ID %ID/g %ID %ID/g %ID
Heart 0.85±0.09 0.18±0.02 0.50±0.13 0.09±0.01 0.32±0.07 0.08±0.02
Lungs 2.28±0.41 0.60±0.11 1.35±0.07 0.41±0.04 0.68±0.06 0.21±0.04
Liver 44.6±10.6 73.9±6.3 42.2±9.1 69.2±7.5 30.9±4.2 57.6±5.3
Spleen 75.0±13.1 5.8±0.80 99.5±11.0 6.6±0.38 54.9±1.2 4.7±0.52
Stomach 0.29±0.08 0.14±0.01 0.45±0.17 0.16±0.08 0.28±0.07 0.12±0.01
Small int. 0.35±0.01 0.34±0.05 0.34±0.02 0.28±0.02 0.27±0.07 0.32±0.04
Large int. 0.34±0.04 0.36±0.04 0.27±0.02 0.29±0.14 0.21±0.04 0.26±0.10
Kidneys 3.9±0.45 1.8±0.15 4.0±0.44 1.65±0.26 3.0±0.43 1.42±0.21
Muscle 0.19±0.03 – 0.21±0.05 – 0.13±0.03 –
Femur 7.1±1.4 0.63±0.08 8.4±0.47 0.76±0.02 5.3±0.85 0.52±0.04
Salivary gl. 0.54±0.06 0.12±0.004 0.52±0.14 0.10±0.02 0.44±0.04 0.10±0.03
Blood 1.8±0.18 – 1.0±0.18 – 0.53±0.18 –
Liver:spleen 0.60±0.18 12.7±2.1 0.42±0.10 10.5±1.3 0.56±0.08 12.1±1.7
Liver:femur 6.28±1.94 116.8±17.2 5.02±1.12 91.1±10.2 5.83±1.23 110.8±13.5
Spleen:femur 10.6±2.78 9.2±1.7 11.9±1.47 8.7±0.56 10.4±1.68 9.1±1.22
Liver:kidneys 11.4±3.0 40.9±4.8 10.6±2.6 42.0±8.1 10.3±2.0 40.5±7.1
Spleen:kidneys 19.2±4.0 3.2±0.52 24.9±3.9 4.0±0.67 18.3±2.7 3.3±0.61
Femur:kidneys 1.8±0.42 0.35±0.05 2.1±0.26 0.46±0.07 1.8±0.38 0.37±0.06
%ID and %ID/g were calculated after ex vivo tissue counting; mean ± SD
Fig. 1 Radioactivity distribution 7 days after inoculation of mice with
[89Zr]oxinate4- and [
111In]oxinate3-labelled eGFP-5T33 cells. %ID and
%ID/g were calculated after ex vivo tissue counting and are given as
mean ± SD (n=3 per group). Data are selected from Table 3 to show
accumulation of 89Zr and 111In in haemopoietic tissues and kidneys (the
main locations of radioactivity)
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superior to that of cells labelled with 64Cu complexes of PTSM
[11, 20–22] and GTSM [23] or with 18F-FDG. The superior
retention of 89Zr compared to 111In by eGFP-5T33 cells in vivo
is inferred from the much slower transfer of 89Zr than 111In
from liver, spleen and bone marrow to kidneys and suggests
that replacing 111In SPECTwith 89Zr PETcan extend the period
over which cells can be reliably tracked in vivo; indeed, we
have been able to acquire good PET images up to 2 weeks post-
inoculation. The 14-day image showed a similar biodistribution
of radioactivity to that seen at 7 days in the same mouse
suggesting that the radiolabel continued to be retained by
5T33 cells in vivo (Fig. S4).
The overall biodistribution observed with both 111In- and
89Zr-labelled cells (initial uptake in lung followed by migra-
tion to liver, spleen and bone marrow) is consistent with
earlier studies of the migration of related murine myeloma
cells, by histology and by radiolabelling with 51Cr [35]. Organ
to organ uptake ratios among the main target organs (liver,
spleen, bone marrow) did not vary significantly throughout
the study, either for 89Zr or 111In, suggesting that labelled cells,
or radioactivity, did not migrate from one haematopoietic
tissue to another and that the radiolabel used did not change
the tissue preference of eGFP-5T33 cells. To test the implicit
assumption that migration of radioactivity from liver, spleen
and bone marrow to kidney and bladder is an indicator of
gradual efflux of radioactivity from living or dead labelled
cells, we examined the distribution of activity after injection of
[89Zr]oxinate4 and that of cells that had been killed/lysed after
radiolabelling with 89Zr and 111In. The resulting
biodistribution qualitatively resembled that seen with labelled
healthy cells, but both 89Zr- and 111In-labelled cell lysate
showed greatly increased uptake in kidney and also liver and
reduced uptake in spleen, even at early time points (30 min,
24 h, Fig. 3), compared to labelled healthy cells. This contrast
in behaviour of 89Zr injected in the form of living labelled cells
and dead/lysed labelled cells is consistent with the hypothesis
that migration of radioactivity from initially targeted organs to
kidney and bladder is a non-invasive marker for efflux of
radioactivity from living or dying labelled cells in vivo.
89Zr injected in the form of neutralised [89Zr]-oxalate also
shows marked differences from the behaviour of labelled
cells, consistent with the assumption that the images obtained
after injection of 89Zr-labelled cells reflect the location of the
cells. With [89Zr]oxinate4 significant uptake in heart was
observed that was not seen with labelled cells, while
[89Zr]oxalate shows gradual skeletal accumulation: radioac-
tivity can be imaged in the joints as early as 15 min post-
injection [42, 43].
The novel experimental approach of ex vivo FACS sorting
of eGFP-positive and eGFP-negative populations from organ
homogenates, followed by radiation counting of these frac-
tions, showed that the radioactivity in the target tissues
Table 3 Radioactivity distribution 7 days after i.v. inoculation of C57Bl/KaLwRij mice with [89Zr]oxinate4- and [
111In]oxinate3-labelled eGFP-5T33
cells
Organ 89Zr-oxine 89Zr-oxine 111In-oxine 111In-oxine
7 days (n=3) 7 days (n=3) 7 days (n=3) 7 days (n=3)
%ID/g %ID %ID/g %ID
Heart 0.24±0.04 0.03±0.005 0.71±0.12 0.12±0.02
Lungs 0.35±0.04 0.09±0.009 0.66±0.05 0.20±0.009
Liver 50.6±8.9 58.2±5.5 33.4±2.1 43.8±3.1
Spleen 129.5±26.5 7.9±0.76 71.6±6.9 4.59±0.34
Stomach 0.43±0.12 0.12±0.06 0.66±0.14 0.19±0.03
Small int. 0.17±0.07 0.16±0.06 0.43±0.11 0.44±0.12
Large int. 0.17±0.08 0.18±0.09 0.45±0.07 0.58±0.16
Kidneys 2.64±0.39 0.96±0.06 9.9±0.64 4.2±0.39
Muscle 0.16±0.02 – 0.43±0.05 –
Femur 10.8±2.5 0.88±0.12 6.0±0.5 0.56±0.04
Salivary gl. 0.40±0.03 0.06±0.01 1.96±0.24 0.35±0.08
Blood 0.23±0.1 – 0.22±0.06 –
Liver:spleen 0.39±0.11 7.3±1.0 0.47±0.05 9.5±1.0
Liver:femur 4.69±1.36 66.0±11.2 5.57±0.58 78.7±8.4
Spleen:femur 12.0±3.71 9.0±1.5 11.9±1.52 8.3±0.9
Liver:kidneys 19.2±4.4 60.6±6.7 3.4±0.4 10.5±1.25
Spleen:kidneys 49.1±12.4 8.3±0.92 7.23±0.8 1.1±0.13
Femur:kidneys 4.1±1.1 0.92±0.14 0.61±0.06 0.13±0.02
%ID and %ID/g were calculated after ex vivo tissue counting and are given as mean ± SD (n=3 per group)
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remains associated with the originally labelled eGFP-
expressing cells (Fig. 4), and hence that these labelled cells
remain alive during the 7 days in vivo; 96 % of liver radioac-
tivity, 99% of spleen radioactivity and >99% of bone marrow
radioactivity remains associated with eGFP-positive cells at
2 days, falling to 95, 92 and 98 %, respectively, by 7 days.
Although we observed excellent in vivo survival of labelled
eGFP-5T33 cells in this study, a more thorough understanding
of the possible cytotoxic effects of the wider use of both 89Zr
and 111In labelling of cells is required for a proper
interpretation of cell tracking data generally. This ex vivo
FACS-based method provides a potential experimental ap-
proach to this challenging problem.
These highly promising results warrant further develop-
ment including refinement of the radiosynthesis and labelling
process to improve radiochemical and cell labelling yields,
select the most suitable medium for cell labelling and elimi-
nate undesirable use of chloroform, and determine the func-
tional and survival effects of labelling in a variety of cell types,
prior to evaluation of the method for cell tracking in humans.
Fig. 2 PET/CT and SPECT/CT images of C57Bl/KaLwRij mice inocu-
lated with [89Zr]oxinate4- or [
111In]oxinate3-labelled eGFP-5T33 cells.
Scans of 111In (top) and 89Zr (bottom) are reported from 30 min to 7 days
after i.v. inoculation of C57Bl/KaLwRij mice with 107 eGFP-5T33 cells
labelled with 5 MBq [89Zr]oxinate4 or 10 MBq [
111In]oxinate3. Image
scales were adjusted to the maximum activity concentration within each
image except for the 2-h images where the activity scale was adjusted to
the maximum activity per voxel used in the 30-min image in order to
quantitatively visualise the rapid change in the early homing pattern of
eGFP-5T33 cells after i.v. inoculation
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While estimates of likely dosimetry in humans have not yet
been performed, it will also be important to assess the poten-
tial advantages of cell tracking by PET with 89Zr against the
likely increased radiation burden per megabecquerel associat-
ed with 89Zr, balancing the increased dose per decay, the low
positron yield of 89Zr and the increased detection efficiency of
PET compared to SPECT.
Conclusion
The new lipophilic, metastable complex of 89Zr can radiolabel
a range of cells, independently of specific phenotypes, pro-
viding a long-sought solution to the unmet need for a long
half-life positron-emitting radiolabel to replace 111In for cell
migration imaging. In addition to the expected advantages
(enhanced sensitivity, resolution and quantification) of cell
tracking with PET rather than scintigraphy or SPECT, 89Zr
shows less efflux from eGFP-5T33 cells in vitro and in vivo
than 111In during at least 7 days after labelling. The excellent
in vivo survival and retention of radioactivity by the cells at
7 days, coupled with the demonstrated ability to acquire useful
PET images up to 14 days, significantly extend the typical
period over which cells can be tracked by radionuclide imag-
ing with directly labelled cells. This method offers a potential
solution to the emerging need for a long half-life PET tracer
for cell tracking in vivo and deserves further evaluation of its
effects on survival and behaviour of different cell types, and
the dosimetric and radiobiological implications of application
in humans.
Fig. 3 SPECT/CT and PET/CT images of mice injected with
radiolabelled eGFP-5T33 cell lysates or [89Zr]oxinate4. a, b SPECT/CT
images ofmice injectedwith lysates of 1.1×106 eGFP-5T33 cells labelled
with 1.1 MBq [111In]oxinate3 at 1 and 24 h post-injection, respectively. c
PET/CT image of mouse 24 h after injection with 4 MBq [89Zr]oxinate4.
d, e PET/CT images of mice injected with lysates of 1.1×106 eGFP-5T33
cells labelled with 0.9 MBq [89Zr]oxinate4 at 1 and 24 h post-injection,
respectively
Fig. 4 89Zr activities in
eGFP-positive and eGFP-
negative cell populations sorted
from organ samples. Liver, spleen
and femoral marrow (BM) organ
homogenates were harvested
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